Objective Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism
treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban …

Aims To evaluate if rivaroxaban, an oral factor Xa (FXa) inhibitor, could modify the
expression in vitro of inflammatory and oxidative stress biomarkers in abdominal aortic …

Abstract Objective Activated factor X (FXa) plays a key role in the coagulation cascade,
whereas accumulating evidence suggests that it also contributes to the pathophysiology of …

Intraluminal thrombus is a consistent feature of human abdominal aortic aneurysm (AAA).
Coagulation factor Xa (FXa) catalyses FII to thrombin (FIIa). We examined the effect of …

Accumulating evidence suggests that activated factor X (FXa), a key coagulation factor,
plays an important role in the development of vascular inflammation through activation of …

Aims Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral
anticoagulant approved for secondary prevention after acute coronary syndrome. Our …

Atherosclerosis is a progressive inflammatory vascular disorder, complicated by plaque
rupture and subsequently atherothrombosis. In vitro studies indicate that key clotting …

Abdominal aortic aneurysm (AAA) is a chronic inflammatory disease characterized by aortic
dilatation and predominantly affects an elderly population. Accumulating evidence suggests …

Activated factor X (FXa) plays a central role in the coagulation cascade, while it also
mediates vascular function through activation of protease-activated receptors (PARs). Here …

Factor Xa (FXa) is the key serine protease of the coagulation cascade as it is the point of
convergence of the intrinsic and extrinsic pathways, leading to the formation of thrombin …